We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Eyecare company’s plans to raise up to $840mn in second-largest listing of the year stymied by volatile markets
Rising interest rates and stock market sell-off should continue to give investors pause
Pharmaceutical company formerly known as Valeant keeps shedding assets from past deal spree
The need to understand customers led to an extreme product test for the dealmaking pharma boss
A pharma deal with some wrinkles to smooth out to prolong the life of cash flows
As Europe changes austerity tactics, pharma and telecom M&A deals dominate
Warburg will get up to about three times its initial equity investment
Warburg Pincus’s audacity and opportunism is rewarded
International Edition
